Date: 2013-08-26
Type of information: Company acquisition
Acquired company: Amplimmune (USA)
Acquiring company: MedImmune (USA - global biologics arm of AstraZeneca (UK)
Amount: up to $275 million
Terms:
Details: The acquisition will bolster MedImmune’s oncology pipeline by obtaining multiple early-stage assets for its immune-mediated cancer therapy (IMT-C) portfolio, including AMP-514, an anti-programmed cell death 1 (PD-1) monoclonal antibody. AMP-514 is currently in late-stage pre-clinical development with the aim of an investigational new drug (IND) filing before the end of 2013. Amplimmune has also developed two other biologic product candidates: AMP-224 is in Phase 1b trials in cancer; AMP-110 for autoimmune diseases in partnership with Daiichi Sankyo. Other Amplimmune assets include multiple preclinical molecules targeting the B7 pathways.
MedImmune has currently several pre-clinical and clinical stage programmes in immune-mediated cancer therapy. These products include tremelimumab, anti-OX40 mAb and MEDI-4736 (anti-PD-L1 mAb).
Related: Cancer-Oncology